researchoncancer
British pharmaceutical giant AstraZeneca reported earnings that beat market expectations in the second quarter, thanks to its robust growth in cancer drug sales and partner medicine revenue. The company has also upgraded its outlook for fiscal 2024. The company reported earnings per share of $1.24 (€1.14) on total revenue of $12.94 billion (€11.94 billion), representing an increase of 15% and 17% from the same quarter last year at constant exchange rates (CER). The two key metrics topped Wall Street's estimates of $0.99 and $12.65 billion, respectively. Cancer drug sales lifted oncology medici...
Euronews (English)
A new study by the American Cancer Society (ACS) found that a high number of cancer cases and deaths in adults 30 and older were due to factors that could potentially be prevented, like cigarette smoking and poor diet. The findings revealed that 40 per cent of cases and about half of all cancer deaths in the United States are attributed to factors that could be controlled. Cancer cases expected to grow by more than 20% in Europe by 2045 - WHO agencyResearchers analysed the incidence and mortality of 30 types of cancer in relation to 18 modifiable risk factors. “A large number of cancer cases a...
Euronews (English)
Talc was classified as “probably carcinogenic” to humans by the cancer agency of the World Health Organization (WHO). A working group of 29 scientists from 13 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, and published their findings in The Lancet Oncology00384-X/abstract) last week. The classification is the “second highest level of certainty that a substance can cause cancer”. Talc’s previous classification was as a “possible carcinogen.” Talc was classified “on the basis of a combination of limited evidence for cancer in humans (for ovarian cancer)...
Euronews (English)
Why are some lung cancers more difficult to treat than others? A team of researchers may have found a new clue. A recent study found that two specific genetic mutations influence cancerous cells and make them more likely to resist treatment. The mutations concern the genes EGFR, which is involved in cell growth, and TP53, which helps regulate cell division and prevent tumours. Mutations in these proteins are often hallmarks of cancer which is why the team of researchers from the University College London (UCL), the UK-based Francis Crick Institute and AstraZeneca investigated them using mouse ...
Euronews (English)
Laura, 33, was diagnosed with stage three breast cancer about eight months ago. Based in Valencia, Spain, she says that everything has changed since. “From how I see myself as a person to the way I deal with things, nothing is the same as before," she tells Euronews. "It’s as if I am a completely different person. I’m not me anymore, I am another version of myself". After three operations, a chemo, and a radiotherapy, Laura — a doctor herself — is undergoing a hormone treatment. Pedro, meanwhile, has survived lung cancer. Yet, this 62-year-old Valencian, a former employee of a plastic recyclin...
Euronews (English)
Rectal cancer disappeared in all patients involved in a small clinical trial of a new immunotherapy treatment, according to updated results released this month. The study was a collaboration between the US-based Memorial Sloan Kettering Cancer Center (MSK) and the pharmaceutical company GSK. It looked at a new drug called dostarlimab-gxly to treat patients with a specific type of rectal cancer caused by a genetic mutation. “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these pat...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら